Elutia to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Elutia, Inc. - Class A (ELUT)
Company Research
Source: GlobeNewswire
SILVER SPRING, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a leader in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, Matt Ferguson, Chief Financial Officer, and Dr. Michelle LeRoux Williams, Chief Scientific Officer, will participate in 1x1 investor meetings at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 21, 2024. Institutional investors interested in meeting with management during the conference may reach out to their Canaccord representative. About ElutiaElutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com. Investors:M
Show less
Read more
Impact Snapshot
Event Time:
ELUT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELUT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELUT alerts
High impacting Elutia, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
ELUT
News
- Cardiac Resynchronization Therapy (CRT) Market Insights, Competitive Landscape and Market Forecast 2024-2030 [Yahoo! Finance]Yahoo! Finance
- Elutia Awarded Cardiac Rhythm Management Devices Agreement with Premier, Inc.GlobeNewswire
- Elutia Inc. (NASDAQ: ELUT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $10.00 price target on the stock.MarketBeat
- Elutia Inc (ELUT) Q3 2024 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges [Yahoo! Finance]Yahoo! Finance
- Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025 [Yahoo! Finance]Yahoo! Finance
ELUT
Sec Filings
- 12/11/24 - Form 4
- 12/11/24 - Form 4
- 12/11/24 - Form 4
- ELUT's page on the SEC website